AngioDynamics receives FDA approval for study
Compartilhar
AngioDynamics (NASDAQ:ANGO) announced that the U.S. Food and Drug Administration approved its Investigational Device Exemption application to begin the RELIEF feasibility study.
AngioDynamics (NASDAQ:ANGO) announced that the U.S. Food and Drug Administration approved its Investigational Device Exemption application to begin the RELIEF feasibility study.
